CHRONIC LYMPHOCYTIC LEUKEMIA

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…

This study tests whether extra COVID-19 vaccine doses are safe and work well for people with weakened immune systems, such as those with HIV, organ transplants, or blood cancers. Around 960 participants will receive different booster schedules to see which one boosts their protec…

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for periods of time. About 60 adults with untreated CLL who need therapy will receive the combination. The goal i…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the…

This phase 3 trial tests whether acalabrutinib is as effective as ibrutinib for people with high-risk chronic lymphocytic leukemia (CLL) who have already tried other treatments. About 533 participants will receive either acalabrutinib or ibrutinib pills. The main goal is to see h…

This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Th…

This phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This phase 3 trial compares the targeted drug acalabrutinib against two standard combination therapies (idelalisib plus rituximab or bendamustine plus rituximab) in 310 adults with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main …

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination works better than either drug alone to control the cancer. About…

This phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About …

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The approach uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main…

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…

This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look…

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This observational study follows 151 Italian adults with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib between May 2021 and April 2022. Researchers want to see how long patients continue the drug and why they might stop, providing real-world insights beyond …

This early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …

This early-phase trial tests two oral drugs—acalabrutinib and ceralasertib—in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has stopped responding to other treatments. The main goal is to check safety and find the right dose. It is not yet known if the combinat…

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a …

This phase II study tests a combination of two drugs, venetoclax and rituximab, in 25 people with chronic lymphocytic leukemia (CLL) that has relapsed or not responded to treatment. The goal is to see how well the combination works and how safe it is. Participants receive venetoc…

This phase 1 study tests a combination of two drugs, ibrutinib and obinutuzumab, in 54 people with chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. The main goal is to check safety and find the best dosing schedule. Researchers will also l…

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib because of side effects. The main goal is to see how many patients have their tumors shri…

This study tests a combination of two drugs, duvelisib and venetoclax, in 55 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. Duvelisib blocks a protein that helps cancer cells survive, while venetoclax targets another survival protein.…

This early-phase study tests a new treatment called FT819 for people with B-cell cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The goal is to find a safe dose and see if the therapy can shrink tumors. About 54 participants will receive FT819 alo…

This phase 2 trial tests a personalized approach for young adults (18-65) with high-risk chronic lymphocytic leukemia (CLL) who haven't been treated before. Patients first get a combination of venetoclax and obinutuzumab, then their treatment is adjusted based on whether cancer c…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This phase 3 trial compares the experimental drug nemtabrutinib (a daily pill) against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who lack a specific genetic change (TP53 mutation)…

This phase 3 trial tests whether the targeted drug zanubrutinib works better than the standard chemo combination of bendamustine plus rituximab for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 590 participants who cannot tole…

This study follows 192 people with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug for at least 24 months and how it works in different groups, like those new to treatment …

This study tests a combination of four drugs (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV gene). The goal is to see if this combo can achieve…

This phase 2 study is testing a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if this triple therapy can improve complete remission rates. The study enrolle…

This phase 2 trial is testing whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve very deep remission. The goal is to see if patients can then safely stop all treatment for a period. The study involves 118 ad…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …

This phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…

This study tests two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if the combination can make cancer undetectable using a sensitive blood test. The treatment length is guided by…

This study tests a new targeted drug, IPI-145, added to standard chemotherapy and immunotherapy (FCR) for younger adults (18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can achieve deep remissions where no cancer cells …

This phase 2 trial is testing whether adding venetoclax to ibrutinib can eliminate resistance mutations in people with chronic lymphocytic leukemia (CLL) who have developed resistance to ibrutinib alone. The study enrolls 28 participants who are already taking ibrutinib and have …

This early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests whether adding a new targeted drug (pirtobrutinib) to a standard two-drug combination (venetoclax and rituximab) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma live longer without their cancer getting worse. About 600 adults who h…

This phase 3 trial compares a new oral targeted drug, pirtobrutinib, against a standard chemo-immunotherapy combination (bendamustine plus rituximab) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 309 participants will be randomly assig…

This early-phase study tests an experimental drug called ABBV-453, given with another cancer drug (obinutuzumab), in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. About 60 participa…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely increase their dose of the drug venetoclax faster than the usual 5-week schedule. About 40 participants with newly diagnosed or returning disease will be grouped…

This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to re…

This early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This early-phase study tests a new cell therapy called huCART19-IL18 for people with CD19-positive blood cancers (like some leukemias and lymphomas) that have relapsed or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better t…

This study tests a new drug, ibrutinib, added to standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can clear all signs of leukemia from the bone marrow (called MRD-negative complete response)…

This early-phase study tests whether adding loncastuximab tesirine to the standard drug acalabrutinib is safe and effective for people with chronic lymphocytic leukemia (CLL). About 24 adults with CLL will receive the combination to find the best dose and see if it can make the c…

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

This study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …

This phase 2 trial tests whether adding cirmtuzumab to venetoclax can clear remaining leukemia cells in people with chronic lymphocytic leukemia (CLL) who still have detectable disease after standard treatment. Only 5 participants are enrolled, and the main goal is to see if the …

This study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…

This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…

This phase II trial tests whether ruxolitinib (Jakafi) can reduce fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet ready for standard treatment. Ten participants will take the drug and report their fatigue levels using a simple questionnaire. The goal is …

This study looks at whether exercise and weight management can help reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL will take part. Participants will be randomly assigned to start the program right away or after a wait…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) in real-life settings in Romania. Researchers will collect data from 250 patients over three years to see how long they stay on the drug, why they stop, and how effective …

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why …

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The go…

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…

This study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—th…

This study watches 50 people with chronic lymphocytic leukemia (CLL) who are starting a type of drug called a BTK inhibitor. These drugs can cause high blood pressure and irregular heartbeats. Participants will use a wearable device at home to track their heart rhythm and blood p…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to un…

This observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and …

This study follows 1,000 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in France to see how they are actually treated in everyday clinics, not just in controlled trials. Researchers will track which therapies patients receive, in what order, a…